NCT05698043

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(5) 80/20/10mg

An Open Label, Randomized, Single Dose, 2-sequence, 4-period, Cross-over Clinical Trial to Evaluate the Pharmacokinetics and the Tolerability of CKD-386(5) With Co-administration of D013, D326, and D337 in Healthy Adult Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 63 (actual)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Accepted

Summary

A Clinical Trial to evaluate the Pharmacokinetics and Tolerability of CKD-386(5)

Detailed description

An open label, randomized, single dose, 2-sequence, 4-period, cross-over clinical trial to evaluate the pharmacokinetics and the tolerability of CKD-386(5) with co-administration of D013, D326, and D337 in healthy adult volunteers

Conditions

• Hypertension and Dyslipidemia

Interventions

Type	Name	Description
DRUG	CKD-386(5)	Test
DRUG	D013, D326, D337	Reference

Timeline

• Start date: 2023-07-17
• Primary completion: 2023-09-01
• Completion: 2023-09-26
• First posted: 2023-01-26
• Last updated: 2023-11-01

Locations

1 site across 1 country: South Korea